SIC 2834 – Pharmaceutical Preparations
| Valuation | |
|---|---|
| Market Cap ($M) | 1,177.15 |
| Enterprise Value ($M) | 885.32 |
| Book Value ($M) | 288.40 |
| Book Value / Share | 6.11 |
| Price / Book | 4.08 |
| NCAV ($M) | 279.97 |
| NCAV / Share | 5.93 |
| Price / NCAV | 4.20 |
| Profitability (mra) | |
|---|---|
| Return on Invested Capital (ROIC) | -0.30 |
| Return on Assets (ROA) | -0.31 |
| Return on Equity (ROE) | -0.33 |
| Liquidity (mrq) | |
|---|---|
| Quick Ratio | 17.44 |
| Current Ratio | 17.44 |
| Balance Sheet (mrq) ($M) | |
|---|---|
| Current Assets | 297.00 |
| Assets | 305.43 |
| Liabilities | 17.03 |
| Debt | n/a |
| Equity | n/a |
| Income Statement (mra) ($M) | |
|---|---|
| Revenue | 0.00 |
| Operating Income | 0.00 |
| Net Income | 0.00 |
| Cash Flow Statement (mra) ($M) | |
|---|---|
| Cash From Operations | 0.00 |
| Cash from Investing | 0.00 |
| Cash from Financing | 0.00 |
(click for more detail) |
|
| File Date | Form | Activist 13D/G Investors | Ownership (%) |
Change (%) |
|---|---|---|---|---|
| 13G/A | Commodore Capital Lp | 8.70 | 41.29 | |
| 13G/A | Venrock Healthcare Capital Partners III, L.P. | 8.50 | 36.26 | |
| 13G/A | Fairmount Funds Management LLC | 6.80 | 50.27 | |
| 13G/A | Citadel Advisors Llc | 3.70 | ||
| 13G/A | Ra Capital Management, L.p. | 2.20 | ||
| 13G | Polar Capital Holdings Plc | 5.69 | ||
| 13G | BlackRock, Inc. | 6.20 | 0.00 | |
| 13D/A | 5AM Ventures VI, L.P. | 4.90 | -18.74 | |
| 13D/A | Orbimed Advisors Llc | 16.80 | -11.54 | |
| 13G/A | Pfizer Inc | 0.95 | ||
| 13G/A | Fmr Llc | 14.32 | 33.55 | |
| 13G/A | BML Investment Partners, L.P. | 0.10 |
| Top 13F Investors | Shares (1000) |
Change (%) |
Value ($1000) |
Change (%) |
|---|---|---|---|---|
(click for more detail) |
||||
| Date | Insider Trades | Code | Shares | Value |
|---|---|---|---|---|
(click for more detail) |
||||
| File Date | Form | SEC Filings |
|---|---|---|
| UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q | ||
| UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q | ||
| UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K | ||
(click for more detail) |
||
| Short Volume | |||
|---|---|---|---|
| Market Date | Short Volume | Total Volume | Short Volume Ratio |
| 32,111 | 211,591 | 15.18 | |
| 38,238 | 166,271 | 23.00 | |
| 31,845 | 252,047 | 12.63 | |
| 100,236 | 286,924 | 34.93 | |
(click for more detail) |
|||
| Similar Companies | |
|---|---|
| DVAX – Dynavax Technologies Corporation | EDIT – Editas Medicine, Inc. |
| ELEV – Elevation Oncology, Inc. | ENTA – Enanta Pharmaceuticals, Inc. |
| ERAS – Erasca, Inc. |
Financial data and stock pages provided by
Fintel.io